Stem Cell Transplantation ( DrugBank: - )


10 diseases
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica23
19Lysosomal storage disease15
20Adrenoleukodystrophy5
46Malignant rheumatoid arthritis3
65Primary immunodeficiency42
90Retinitis pigmentosa1
125Hereditary diffuse leukoencephalopathy with spheroid1
164Oculocutaneous albinism5
234Peroxisomal disease (except Adrenoleukodystrophy)2
326Osteopetrosis7

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,340Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

19. Lysosomal storage disease


Clinical trials : 899Drugs : 684 - (DrugBank : 99) / Drug target genes : 51 - Drug target pathways : 182 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

20. Adrenoleukodystrophy


Clinical trials : 61Drugs : 90 - (DrugBank : 31) / Drug target genes : 23 - Drug target pathways : 126 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

46. Malignant rheumatoid arthritis


Clinical trials : 4,356Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

65. Primary immunodeficiency


Clinical trials : 500Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

90. Retinitis pigmentosa


Clinical trials : 147Drugs : 176 - (DrugBank : 43) / Drug target genes : 49 - Drug target pathways : 110 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

125. Hereditary diffuse leukoencephalopathy with spheroid


Clinical trial : 1Drugs : 9 - (DrugBank : 1) / Drug target gene : 0 - Drug target pathway : 0
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

164. Oculocutaneous albinism


Clinical trials : 15Drugs : 54 - (DrugBank : 34) / Drug target genes : 35 - Drug target pathways : 141 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

234. Peroxisomal disease (except Adrenoleukodystrophy)


Clinical trials : 39Drugs : 35 - (DrugBank : 12) / Drug target genes : 13 - Drug target pathways : 45 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

326. Osteopetrosis


Clinical trials : 18Drugs : 43 - (DrugBank : 14) / Drug target genes : 17 - Drug target pathways : 82 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries